← board
NNVC
distress 7/10 · high distress / dilution risk$1.57+4%today-22% from 52w high
Revenue
pre-revenue
Liquidity
$3M
Runway
0.4 yrs
Shares 1y
+24%
Price & events
+37.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.6%
1D
-11.0%
1W
+20.2%
1M
+21.2%
3M
+37.0%
6M
-10.0%
1Y
-33.8%
2Y
-62.9%
5Y
-50.5%
All
Overview
- Market Cap
- $34.09M
- Volume
- 53.14K
- 52 Week Range
- $0.85 – $2.03
- Total Shares
- 21.65M
- Float Shares
- 21.08M
- Short %
- 3.96%
- % Held by Insiders
- 2.61%
- % Held by Institutions
- 8.27%
- RVOL
- 0.14x
- Beta
- 1.67
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $6 (+281% upside) · 2 analysts
- 2026-07-06Noble Capital MarketsOutperform
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.